Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

J.-F. Blanc; Stephen L. Chan; J.O. Park; Baek‐Yeol Ryoo; Chung‐Jen Yen; Masatoshi Kudo; Rtp Poon; Davide Pastorelli; Ari David Baron; Tatiana Pfiffer; Takuji Okusaka; Kateřina Kubáčková; Jörg Trojan; Javier Sastre; Ian Chau; Paolo Abada; Samuel Chang; Ling Yang; Alice Zhu

doi:10.1016/s0168-8278(16)01325-8

Article2016

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Masatoshi Kudo, Etsuro Hatano, Shinichi Ohkawa, Hirofumi Fujii, Akihide Masumoto, Junji Furuse, Yoshiyuki Wada, Hiroshi Ishii, Shuntaro Obi, Shuichi Kaneko, Seiji Kawazoe, Osamu Yokosuka, Masafumi Ikeda, Katsuaki Ukai, Sojiro Morita, Akihito Tsuji, Toshihiro Kudo, Mitsuo Shimada, Yukio Osaki, Ryosuke Tateishi, Gen Sugiyama, Paolo Abada, Ling Yang, Takuji Okusaka, Andrew X. Zhu

Article2016

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia-Jui Yen, Kuan‐Der Lee, Shao-Chun Chang, Ling Yang, Paolo Abada, Ian Chau

Article2015

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.

Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia‐Jui Yen, Kuan‐Der Lee, Ling Yang, Ian Chau

Article2015

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial

Shinichi Ohkawa, Takuji Okusaka, Masatoshi Kudo, Etsuro Hatano, Hirofumi Fujii, Akihide Masumoto, Junji Furuse, Yoshiyuki Wada, Hiroshi Ishii, Shuntaro Obi, Kuniaki Arai, Seiji Kawazoe, Osamu Yokosuka, Masafumi Ikeda, Katsuaki Ukai, Sojiro Morita, Hiroya Asou, Paolo Abada, Lingwei Yang, Andrew X. Zhu

Editorial Material2017

Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm

Masatoshi Kudo

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

Discussion(0)

Related publications

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial

Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm